
'Doctor said I had testicular cancer, in my chest, and I was pregnant'
Anthony Bianco, who was a 21-year-old university student at the time, thought his recurring chest infections were down to working and playing too hard. He said: 'I was in my last year of university and it's fair to say I was burning the candle at both ends. I had these recurring symptoms of getting a slight cough and a fever, but it would go away and I would think nothing of it. However, the cough progressively got worse, becoming like a smoker's cough, even though I'm a non-smoker and have never smoked in my life.'
While Anthony's doctor wasn't initially concerned, a history of pneumonia prompted an X-ray, which raised alarms. 'He put the chest X-ray on the screen and then all I could see was this massive white cloud on my chest. And I'm thinking, 'Oh, s**t. I'm screwed,' because it was 11 by 15 centimetres,' he said.
His doctor initially suspected lymphoma - a type of blood cancer that affects the lymphatic system and weakens the immune system. Anthony underwent surgery to remove a lymph node from his neck, but the results came back negative. A second operation was then carried out to biopsy the mass in his chest and the findings were startling.
'When I was called in for my diagnosis, the first thing they said to me was, 'You've got testicular cancer,'' Anthony said. 'I started to panic because I'm thinking it's spread everywhere and I'm not going to make it. However, they did loads of scans and blood tests and they found that the cancer was only in my chest area.'
Anthony was diagnosed with a primary mediastinal non-seminomatous germ cell tumour (PMNSGCT) - a rare type of cancer that develops from germ cells. These cells typically form tumours in the testicles or ovaries, but in rare cases, they can appear elsewhere in the body.
This unusual placement is linked to how the body develops in the womb. As organs form, germ cells migrate to their final destinations, but occasionally, some are left behind in other areas. Years later, these misplaced cells can become cancerous, causing tumours to grow in unexpected places, like the chest.
This type of tumour can also produce unusual test results, as was the case for Anthony. 'The difference between this germ cell tumour and testicular cancer is that this particular tumour releases proteins that I shouldn't have,' he says.
'They're the same proteins that are released in the bloodstream when women are pregnant. My blood results were showing up as positive on a pregnancy test like I was two weeks pregnant. My first response was, 'Is it mine?' I had to find humour to deal with the hand grenade that had just been thrown into my life.'
While Anthony was able to see the funny side of his diagnosis, PMNSGCTs is a potentially deadly form of cancer, as it has a five-year survival rate of around 40%. There were further risks as it was growing around his vital organs. "It was wrapped around my heart and lungs to the point where it was interfering with my blood flow,' he said.
'Just before I was diagnosed, it had started pushing the veins against my chest so you could clearly see them appear in a spider-like pattern. That was the only sort of physical indication of it, as well as a swelling in my neck.'
Treatment typically involves intensive chemotherapy to shrink the tumour, followed up by surgery to remove any remaining mass - a procedure that carries risks due to the tumour's proximity to vital organs. Anthony responded well to chemotherapy, and the tumour shrank so significantly that doctors couldn't tell whether it was still active, reduced to scar tissue, or gone entirely.
After continued monitoring, he was deemed 'clear' in late 1995 and reached the milestone of five-years cancer-free in 2000. Now a father-of-two aged 51, Anthony recalls being conflicted over how the treatment could affect his fertility at the time of his diagnosis back in 1994.
'I did ask my doctor about the fertility question but that's not something you really deal with as a 21-year-old,' he said. 'He said it was possible I could be left infertile, but frankly at the time I just wanted to just get things going with treatment. I was trying to stay alive, and I didn't care.
'I got tested a couple of years later and it was fine. I've got two daughters, 11 and 14,' he said. 'But then I didn't want any more kids, so I've made sure of that.'
Having survived his ordeal, Anthony would love to see more awareness, funding and research directed at rare cancers, including the one he endured.
'There's no research directed at rare cancers, and you basically get the dregs of other research from other more common ones, which unfortunately leads to poor survival rates. If you have cancer as a young adult, you're a statistical outlier, and it's usually a rare one,' he explains.
'My doctor said I had a better chance of winning the lottery than getting this kind of cancer. And I checked. The lottery odds are one in 8.5 million and this cancer is one in 10 million, which annoys me because I still haven't won the lottery.
'But going through this changed a lot of my attitudes,' he adds. 'While I've done a lot with my life, sometimes the voice in my head is asking, 'Are you doing enough?' I think the biggest mistake anyone could ever make is to think they have time because you have no idea when your time's up.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Guardian
3 days ago
- The Guardian
Superbugs could kill millions more and cost $2tn a year by 2050, models show
Superbugs could cause millions more people to die worldwide and cost the global economy just under $2tn a year by 2050, modelling shows. A UK government-funded study shows that without concerted action, increased rates of antimicrobial resistance (AMR) could lead to global annual GDP losses of $1.7tn over the next quarter of a century. The research, by the Center for Global Development thinktank, found the US, UK and EU economies would be among the hardest hit, prompting accusations that recent swingeing aid cuts are self-defeating. On Thursday, the UK government announced it was axing funding for the Fleming fund, which combats AMR in low- and middle-income countries, as part of wider aid cuts. The Trump administration has confirmed $9bn in cuts to its foreign aid budget, while a number of European countries have also reduced spending on overseas aid. Anthony McDonnell, the lead author and the research and a policy fellow at the Center for Global Development, said: 'When we conducted our research on the economic impacts of antimicrobial resistance, it was anticipated that resistance rates would continue to follow historical trends. 'However, the sudden cuts to Official Development Assistance by the US, which has cut its aid spend by roughly 80%; the UK, which has announced aid cuts from 0.5% to 0.3% of gross national income; and substantial reductions by France, Germany, and others, could drive up resistance rates in line with the most pessimistic scenario in our research. 'Even countries that have been successful in keeping AMR rates under control cannot afford to be complacent. Unless AMR programmes are protected from aid cuts, resistance rates across the world will likely increase at a rate in line with the worst-affected countries. 'This would result in millions more people dying worldwide, including across G7 nations. Investing in treatment for bacterial infections now will save lives and deliver billions in long-term economic returns.' The research calculated the economic and health burden of antibiotic resistance for 122 countries and forecast that in that in this most pessimistic scenario, by 2050, GDP losses in China could reach just under $722bn a year, the US $295.7bn, the EU $187bn, Japan $65.7bn and the UK $58.6bn. According to the Institute for Health Metrics and Evaluation (IHME), deaths from AMR are expected to increase 60% by 2050, with 1.34 million people in the US and 184,000 in the UK alone predicted to die each year from antibiotic resistant bugs, while numbers of those becoming seriously ill from drug-resistant bacteria are also expected to jump. Superbugs increase the number of hospital admissions and lead to longer and more intensive hospital stays, costlier second-line treatments and more complex care, meaning resistant infections are roughly twice as expensive to treat as those for which antibiotics are effective. The study estimates global health costs of treating AMR could increase by just under $176bn a year, while in the UK, they would rise from $900m to $3.7bn and in the US from $15.5bn to just under $57bn. Higher rates of resistant bugs would also shrink the UK, EU and US workforces by 0.8%, 0.6% and 0.4% respectively, the study found. But if countries invest more in tackling superbugs – increasing access to new antibiotics and high-quality treatment of these infections – the US economy would grow $156.2bn a year and the UK $12bn (£9.3bn) by 2050. Responding to the findings, Dr Mohsen Naghavi, a professor of health metrics at IHME, said: 'Today the threat of AMR is increasing, and without immediate action from all stakeholders the medicines we have access to now could stop working, potentially causing a simple infection to become deadly.' That would involve policy changes from the US, European and UK governments, the development of new drugs and ensuring everyone understood that antibiotics were ineffective against viruses, he added. A UK government spokesperson said: 'Our 10-year health plan recognises antimicrobial resistance (AMR) as a major threat and commits to urgently tackle its spread, including through new vaccines. 'We have made important progress - reducing antibiotic use in meat and pioneering a world-first subscription model to incentivise the development of new treatments. We also continue to work closely with international partners to influence global efforts to limit the spread of AMR.'


The Guardian
3 days ago
- The Guardian
Superbugs could kill millions more and cost $2tn a year by 2050, models show
Superbugs could cause millions more people to die worldwide and cost the global economy just under $2tn a year by 2050, modelling shows. A UK government-funded study shows that without concerted action, increased rates of antimicrobial resistance (AMR) could lead to global annual GDP losses of $1.7tn over the next quarter of a century. The research, by the Center for Global Development thinktank, found the US, UK and EU economies would be among the hardest hit, prompting accusations that recent swingeing aid cuts are self-defeating. On Thursday, the UK government announced it was axing funding for the Fleming fund, which combats AMR in low- and middle-income countries, as part of wider aid cuts. The Trump administration has confirmed $9bn in cuts to its foreign aid budget, while a number of European countries have also reduced spending on overseas aid. Anthony McDonnell, the lead author and the research and a policy fellow at the Center for Global Development, said: 'When we conducted our research on the economic impacts of antimicrobial resistance, it was anticipated that resistance rates would continue to follow historical trends. 'However, the sudden cuts to Official Development Assistance by the US, which has cut its aid spend by roughly 80%; the UK, which has announced aid cuts from 0.5% to 0.3% of gross national income; and substantial reductions by France, Germany, and others, could drive up resistance rates in line with the most pessimistic scenario in our research. 'Even countries that have been successful in keeping AMR rates under control cannot afford to be complacent. Unless AMR programmes are protected from aid cuts, resistance rates across the world will likely increase at a rate in line with the worst-affected countries. 'This would result in millions more people dying worldwide, including across G7 nations. Investing in treatment for bacterial infections now will save lives and deliver billions in long-term economic returns.' The research calculated the economic and health burden of antibiotic resistance for 122 countries and forecast that in that in this most pessimistic scenario, by 2050, GDP losses in China could reach just under $722bn a year, the US $295.7bn, the EU $187bn, Japan $65.7bn and the UK $58.6bn. According to the Institute for Health Metrics and Evaluation (IHME), deaths from AMR are expected to increase 60% by 2050, with 1.34 million people in the US and 184,000 in the UK alone predicted to die each year from antibiotic resistant bugs, while numbers of those becoming seriously ill from drug-resistant bacteria are also expected to jump. Superbugs increase the number of hospital admissions and lead to longer and more intensive hospital stays, costlier second-line treatments and more complex care, meaning resistant infections are roughly twice as expensive to treat as those for which antibiotics are effective. The study estimates global health costs of treating AMR could increase by just under $176bn a year, while in the UK, they would rise from $900m to $3.7bn and in the US from $15.5bn to just under $57bn. Higher rates of resistant bugs would also shrink the UK, EU and US workforces by 0.8%, 0.6% and 0.4% respectively, the study found. But if countries invest more in tackling superbugs – increasing access to new antibiotics and high-quality treatment of these infections – the US economy would grow $156.2bn a year and the UK $12bn (£9.3bn) by 2050. Responding to the findings, Dr Mohsen Naghavi, a professor of health metrics at IHME, said: 'Today the threat of AMR is increasing, and without immediate action from all stakeholders the medicines we have access to now could stop working, potentially causing a simple infection to become deadly.' That would involve policy changes from the US, European and UK governments, the development of new drugs and ensuring everyone understood that antibiotics were ineffective against viruses, he added. A UK government spokesperson said: 'Our 10-year health plan recognises antimicrobial resistance (AMR) as a major threat and commits to urgently tackle its spread, including through new vaccines. 'We have made important progress - reducing antibiotic use in meat and pioneering a world-first subscription model to incentivise the development of new treatments. We also continue to work closely with international partners to influence global efforts to limit the spread of AMR.'


BBC News
24-06-2025
- BBC News
Premature baby joins new study at Peterborough hospital
A mum is "forever grateful" to have taken part in a new study focused on treating premature babies who need help breathing. Maria Lazinska, 37, joined a neonatal study at Peterborough City Hospital after her son Anthony was born at about 32 weeks into her pregnancy. Babies born prematurely may need breathing support and can be treated with surfactant - a liquid medicine which helps the lungs function. The research project, SurfsUp, compared two ways of administering the surfactant to babies less than 37 weeks' Kazinska, from Peterborough, said: "Anthony responded so well to the treatment — he grew stronger and more stable with each passing day." Some premature babies have respiratory distress syndrome, which makes it difficult for them to breathe due to their lungs being they can receive breathing support, some need additional treatment with it was administered through a tube inserted into the airway using a laryngoscope - a metal device that holds the airway study said it was effective but challenging and was thought to be painful for compared this to an alternative method of using a supraglottic airway, a different type of airway tube, which researchers said made it easier for doctors and more comfortable for babies. Researchers said it was not known if it was as effective as the standard method, Lazinska's son was the first in the East of England to join SurfsUp, which worked with the Children's Hospital, Glasgow, and Monash Hospital, said: "As a mother, seeing my baby get better filled me with so much joy and hope. I will never forget the relief I felt watching him breathe more easily and fight so bravely."We are forever grateful for this opportunity that gave our little boy a stronger start in life."Dr Nikhil Ganjoo, consultant paediatrician and principal investigator for the study, added: " It is very exciting for our unit to be engaged with Neonatal research with the hard work and dedication of our research nurses and the neonatal nurses. "We currently recruit for four international studies on our neonatal intensive care unit, with one of the studies being the highest recruiting non-commercial trial for our trust." Follow Peterborough news on BBC Sounds, Facebook, Instagram and X.